Medipharm Labs Appoints Former Purdue Pharma Exec As CEO

Medipharm Labs (TSX: LABS) continues to suffer from management turnover. The company today announced that its CEO, Bryan Howcroft, will be stepping down for personal reasons effective immediately. Howcroft was in the role for just six months.

Taking Howcroft’s place within the company is that of David Piddick, whom Medipharm lists as previously serving as a president and CEO of a “Canadian pharmaceutical company.” That pharma company is believed to be Purdue Pharma Canada, whom notably faced numerous lawsuits related to the opioid pandemic which ultimately lead to a bankruptcy filing in the US. Piddick will also serve on the firms board of directors.

Piddick reportedly has over two decades worth of senior leadership experience within the healthcare industry. He currently holds a MBA from Northwestern University.

“In MediPharm, I see one of the very few organizations globally that has the required sophistication to both operate within a stringent Pharma environment, and scale rapidly to capitalize on this growth opportunity. I look forward to contributing my experience in business and corporate development to the team’s current efforts, with a focus on orienting the Company toward both consistent organic growth and accretive M&A activities to drive revenue growth, profitability and value for all stakeholders,” commented Piddick on his appointment.

As part of Piddick’s compensation package, he was issued 14.8 million RSU’s in connection with his appointment, as well as 5.2 million stock options.

Howcroft meanwhile has exited his role from the firm entirely, announcing this morning he will also be vacating his position on the firms board.

Medipharm Labs last traded at $0.145 on the TSX.


Information for this briefing was found via Sedar and MediPharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

2 Responses

Video Articles

IAMGOLD Q3 Earnings: Market Responds With MASSIVE Price Lift

G Mining Q3 Earnings: Costs Down, Production Up

Endeavour Silver Q3 Earnings: On The Upswing

Recommended

Silver47 Hits 606 g/t Over 9.7 Metres Silver Equivalent In Final Assays From 2025 Drill Program At Red Mountain

Altamira Gold Encounters Second Porphyry Body, Hitting 3.5 g/t Gold Over 8.0 Metres

Related News

Medipharm Labs Ships First Topical Products

Medipharm Labs (TSX: LABS) is now in the cannabis topicals business. The company announced this...

Wednesday, March 25, 2020, 08:20:53 AM

MediPharm Labs Revenues Increase 37.8% to $43.38 Million

Medipharm Labs (TSX: LABS) announced third quarter earnings this morning, posting revenues of $43.38 million...

Tuesday, November 12, 2019, 08:44:55 AM

MediPharm Labs, Vivo Cannabis Slump After Announcing All-Stock Deal

MediPharm Labs (TSX: LABS) announced on Thursday an all-equity deal to acquire VIVO Cannabis (TSX:...

Sunday, December 25, 2022, 01:35:00 PM

Medipharm Labs Files Statement Of Claim Against Undisclosed Producer

Medipharm Labs (TSX: LABS) issued a typical Friday evening release today, identifying that the company...

Friday, January 24, 2020, 05:34:50 PM

Hexo Has Filed A $35 Million Counterclaim Against Medipharm Labs

It appears that Hexo Corp (TSX: HEXO) (NYSE: HEXO) has filed a counterclaim against Medipharm...

Thursday, June 18, 2020, 11:48:39 AM